WS
AIMT

Wedbush Securities’s Aimmune Therapeutics AIMT Stock Holding History

Wedbush Securities’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,108
Closed -$420K – 1048
2020
Q2 		$420K Buy
25,108
+1,418
+6% +$24.1K 0.04% 484
2020
Q1 		$342K Sell
23,690
-268
-1% -$6.85K 0.04% 482
2019
Q4 		$802K Sell
23,958
-7,496
-24% -$210K 0.07% 313
2019
Q3 		$659K Buy
31,454
+9,397
+43% +$192K 0.06% 343
2019
Q2 		$459K Buy
22,057
+10,997
+99% +$226K 0.05% 468
2019
Q1 		$247K Buy
11,060
+457
+4% +$10.8K 0.03% 679
2018
Q4 		$254K Buy
10,603
+970
+10% +$25.1K 0.03% 593
2018
Q3 		$263K Sell
9,633
-365
-4% -$10.3K 0.03% 645
2018
Q2 		$269K Buy
9,998
+824
+9% +$25.2K 0.03% 594
2018
Q1 		$292K Buy
+9,174
New +$323K 0.04% 535

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wedbush Securities's AIMT Position: Q3 2020 in Review

Wedbush Securities sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 25,108 shares — an estimated $420K sold.

Wedbush Securities first reported a position in AIMT in Q1 2018 and held it in 10 quarters. The position peaked at $802K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Wedbush Securities reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 25,108 Aimmune Therapeutics shares in Q3 2020, an estimated $420K.
  • Wedbush Securities first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 10 quarters.
  • Wedbush Securities's Aimmune Therapeutics position peaked at $802K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.